However, since CD36 and LOX-1 are molecules in atherosclerosis development and progression, their pharmacological inhibition would be an exciting and promising avenue in developing therapeutic agents to alleviate or even reverse the atherosclerotic plaque formation. Here, OLR1 is linked to atherosclerosis.